PUBLISHER: The Business Research Company | PRODUCT CODE: 1946730
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946730
PD-L1 and PIK3CA testing are molecular diagnostic methods used to identify specific biomarkers that support targeted cancer treatment decisions. PD-L1 testing measures the expression of the programmed death ligand 1 protein on tumor cells to evaluate the likelihood of response to immunotherapies. PIK3CA testing identifies mutations in the phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha gene, which helps determine eligibility for therapies directed at the PI3K pathway.
The primary test types of PD-L1 and PIK3CA testing include immunohistochemistry, next generation sequencing, polymerase chain reaction, and others. Immunohistochemistry is a laboratory method that applies antibodies to detect specific proteins in tissue samples, making it possible to visualize their location and concentration under a microscope. The sample types used are tissue samples and liquid biopsy samples. The distribution channels include direct sales, distributors and resellers, and online sales platforms. The applications involve cancer diagnosis, drug development, research, and other uses, and they serve multiple end users such as hospitals and clinics, laboratories, and pharmaceutical companies.
Tariffs are impacting the pd-l1 and pik3ca testing market by increasing costs for imported sequencing kits, reagents, and diagnostic instruments. Hospitals, laboratories, and pharmaceutical companies in Asia-Pacific and Europe are most affected. Segments such as immunohistochemistry and next-generation sequencing kits face higher import costs. Positive impacts include promoting local manufacturing of reagents and kits, fostering innovation, and reducing dependency on international suppliers.
The pd-l1 and pik3ca testing market research report is one of a series of new reports from The Business Research Company that provides pd-l1 and pik3ca testing market statistics, including pd-l1 and pik3ca testing industry global market size, regional shares, competitors with a pd-l1 and pik3ca testing market share, detailed pd-l1 and pik3ca testing market segments, market trends and opportunities, and any further data you may need to thrive in the pd-l1 and pik3ca testing industry. This pd-l1 and pik3ca testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pd-l1 and pik3ca testing market size has grown rapidly in recent years. It will grow from $1.67 billion in 2025 to $1.93 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to development of pd-l1 and pik3ca assays, adoption in clinical trials, growing cancer prevalence, advancements in molecular diagnostics, awareness of personalized therapy.
The pd-l1 and pik3ca testing market size is expected to see rapid growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to integration of ai in biomarker detection, growth of liquid biopsy applications, expansion in precision oncology, partnerships between diagnostics and pharma companies, regulatory approvals for next-gen assays. Major trends in the forecast period include targeted cancer biomarker testing, ai-based mutation analysis, liquid biopsy adoption, integration with drug development, high-throughput genomic screening.
The growing prevalence of cancer is expected to drive the expansion of the PD-L1 and PIK3CA testing market. Cancer, which is characterized by the uncontrolled growth and spread of abnormal cells, has become more common due to factors such as lifestyle-related risks and an aging population. These factors contribute to higher diagnosis rates and an increased demand for early detection and effective treatment solutions. PD-L1 and PIK3CA testing help manage cancer by providing accurate diagnoses and guiding targeted therapies, which allow treatments to be personalized to individual patients and improve clinical outcomes. For example, in September 2024, the American Cancer Society projected a significant increase in global cancer cases among men, estimating an 84% rise by 2029, from 10.3 million in 2022 to 19 million. This surge in cancer cases is driving the growth of the PD-L1 and PIK3CA testing market.
Key players in the PD-L1 and PIK3CA testing market are focusing on technological advancements, particularly the integration of companion diagnostics, to improve therapeutic targeting and enhance treatment efficacy in oncology. Companion diagnostic integration involves advanced testing systems designed alongside targeted medicines to identify patient groups most likely to benefit from specific treatments based on biomarker profiles. For instance, in October 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, introduced Itovebi (inavolisib) in combination with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. The FDA approved this regimen based on the Phase III INAVO120 study, which showed more than double the progression-free survival compared to palbociclib and fulvestrant alone. This marks Roche's first targeted therapy for HR-positive disease and incorporates a companion diagnostic to identify eligible patients, representing a major step forward in precision medicine for a patient population with limited treatment options.
In September 2025, Labcorp, a U.S.-based provider of comprehensive clinical laboratory services and drug development solutions, purchased select oncology and oncology-related clinical testing assets from BioReference Health for up to $225 million. Through this acquisition, Labcorp seeks to broaden its oncology diagnostics portfolio and enhance nationwide access to high-value cancer testing services by incorporating BioReference's specialized oncology capabilities and client accounts. BioReference Health is a U.S.-based provider of oncology-focused laboratory testing services, delivering advanced cancer diagnostics, clinical testing solutions, and regional clinical laboratory operations.
Major companies operating in the pd-l1 and pik3ca testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.
North America was the largest region in the PD-L1 and PIK3CA testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pd-l1 and pik3ca testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pd-l1 and pik3ca testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The PD-L1 and PIK3CA testing market includes revenues earned by entities through the biomarker testing, molecular diagnostics, genetic mutation detection, generation sequencing services, companion diagnostic testing, pathology interpretation, and clinical trial testing support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
PD-L1 And PIK3CA Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pd-l1 and pik3ca testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pd-l1 and pik3ca testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pd-l1 and pik3ca testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.